hackint0sh/New-Dataset huggingface dataset:
Quantitative analysis will be adopted to investigate the effectiveness of the 'Outdoor Rehab-Fit' App-based physical activity education intervention on the health outcomes of frail older adults. The qualitative component will consist of semi-structure interviews with the frail older adults to understand the acceptability of the intervention. conditions: Physical Inactivity conditions: Frailty studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: mHealth name: Health Talk measure: Feasibility outcome: Recruitment rate measure: Feasibility outcome: Intervention completion rate measure: Feasibility outcome: Attrition rate measure: Feasibility outcome: Attendance measure: Acceptability outcome: Perceived Usefulness on Outdoor Rehab-Fit App measure: Acceptability outcome: Participants' views about the barriers and facilitation of the mHealth program measure: Change in Physical activity level (Objective) at 1 month and 3 months measure: Change in Physical activity level (Subjective) at 1 month and 3 months measure: Change in Exercise self-efficacy at 1 month and 3 months measure: Change in Mental well-being at 1 month and 3 months measure: Change in usage of outdoor exercise facilities sex: ALL minimumAge: 55 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Rehabilitation Sciences, The Hong Kong Polytechnic University status: RECRUITING city: Hong Kong country: Hong Kong name: Janet Lok Chun Lee, PhD role: CONTACT email: lcjlee@polyu.edu.hk lat: 22.27832 lon: 114.17469 hasResults: False
nctId: NCT06326697 id: HIK-AZA-2023-01 briefTitle: Bioequivalence of Azacitidine 300 mg Film-Coated Tablets in Adult Patients With Acute Myeloid Leukaemia (AML) overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2025-01 date: 2025-03 date: 2024-03-22 date: 2024-03-22 name: Hikma Pharmaceuticals LLC class: INDUSTRY briefSummary: A Randomized, Single Oral Dose, Open Label, Two Treatment, Crossover study to investigate the bioequivalence of the Test Product Azacitidine 300 mg Film coated tablets relative to Reference Product Onureg® 300 mg Film Coated Tablets in adult patients with AML under fasting conditions conditions: Acute Myeloid Leukaemia studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: OTHER masking: NONE count: 32 type: ESTIMATED name: Azacitidine name: Onureg measure: Cmax measure: AUC0-t measure: AUC0-∞ measure: Kel measure: Tmax measure: T1/2el measure: Adverse Events (AEs) measure: Change in clinical safety labs sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06326684 id: 88524 briefTitle: Suvorexant and Alcohol overallStatus: NOT_YET_RECRUITING date: 2024-06-15 date: 2027-03-15 date: 2027-03-15 date: 2024-03-22 date: 2024-03-27 name: University of Kentucky class: OTHER name: National Institute on Alcohol Abuse and Alcoholism (NIAAA) briefSummary: This research will translate findings from preclinical research and provide the initial clinical evidence that orexin antagonism reduces motivation for alcohol, as well as other alcohol-associated maladaptive behaviors in people with Alcohol Use Disorder. This study will also provide basic science information about the orexinergic mechanisms underlying the pharmacodynamic effects of alcohol in humans. As such, the outcomes will contribute to our understanding of the clinical neurobiology of Alcohol Use Disorder. Overall, the proposed work seeks to expand the scope of current clinical neuroscience research on alcohol addiction by focusing on orexin, which has strong preclinical evidence supporting its critical role in addiction but remains unstudied in humans. conditions: Alcohol Use Disorder studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: BASIC_SCIENCE masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 30 type: ESTIMATED name: Alcohol name: Placebo name: Suvorexant name: Suvorexant measure: Reinforcing Effects of Alcohol measure: Craving measure: Mood measure: Alcohol Response measure: Heart rate measure: Blood pressure measure: Breath Alcohol Level measure: Temperature measure: Side Effects measure: Delay Discounting measure: n-back Task measure: Stop-Signal Task Inhibitory Failures measure: Sleep sex: ALL minimumAge: 21 Years maximumAge: 55 Years stdAges: ADULT facility: Psychopharmacology of Addiction Laboratory city: Lexington state: Kentucky zip: 40507 country: United States name: William Walton Stoops role: CONTACT phone: 8592575388 email: william.stoops@uky.edu name: William W Stoops, PhD role: PRINCIPAL_INVESTIGATOR lat: 37.98869 lon: -84.47772 hasResults: False
nctId: NCT06326671 id: STXA-BE-03 briefTitle: A Trial to Assess the Bioequivalence of Generic Tiotropium Bromide Inhalation Powder and Reference Product in Healthy Adult Participants Under Fasting Conditions (Pilot) overallStatus: ACTIVE_NOT_RECRUITING date: 2024-02-28 date: 2024-03 date: 2024-04 date: 2024-03-22 date: 2024-03-29 name: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. class: INDUSTRY briefSummary: Primary Objective: To evaluate the pharmacokinetics of Tiotropium Bromide Inhalation Powder (Strength:18 mcg; manufactured by Chia Tai Tianqing Pharmaceutical Group Co. Ltd) and reference products Tiotropium Bromide Inhalation Powder (Spiriva®, Handihaler®, Strength: 18mcg, manufactured by Boehringer Ingelheim Pharmaceuticals, Inc) by oral inhalation of single dose in healthy participants under fasting conditions. conditions: Chronic Obstructive Pulmonary Disease studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: NONE count: 39 type: ACTUAL name: Tiotropium Bromide Inhalation Powder name: Spiriva HandiHaler measure: Peak concentration (Cmax) measure: Area under the plasma concentration versus time curve (AUC) 0-t measure: Area under the plasma concentration versus time curve (AUC) 0-∞ measure: The time to maximum plasma concentration (Tmax) measure: The elimination half-life (t1/2) measure: Terminal elimination rate constant (Kel) sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: Henan (Zhengzhou) Zhonghui Cardiovascular Hospital city: Zhengzhou state: Henan zip: 450003 country: China lat: 34.75778 lon: 113.64861 hasResults: False
nctId: NCT06326658 id: TCM for Frequent AECOPD briefTitle: Bufei Yishen Prescription on Patients With Frequent AECOPD in Stable Stage overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-05-01 date: 2026-10-31 date: 2024-03-22 date: 2024-03-22 name: Henan University of Traditional Chinese Medicine class: OTHER name: The First Affiliated Hospital of Henan University of Traditional Chinese Medicine name: The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine briefSummary: To evaluate the clinical efficacy and health economic advantages of Lung Replenishing and Kidney Enhancing Formula for the treatment of patients with frequent acute exacerbations in the stabilized phase. conditions: Chronic Obstructive Pulmonary Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 848 type: ESTIMATED name: Bufei Yishen Prescription Granule measure: The number of acute exacerbations measure: The number of AECOPD leading to hospitalization and death measure: Time of onset of the first AECOPD measure: Severity of AECOPD measure: Duration of AECOPD measure: Case fatality rate measure: Lung function measure: Score for clinical signs and symptoms measure: 6-minute walking distance (6MWD) measure: The Chronic Obstructive Pulmonary Patient Self-Assessment Test (CAT) measure: The MOS item short fromhealth survey（SF-36） sex: ALL minimumAge: 40 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06326645 id: IRB23-891 briefTitle: Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome overallStatus: NOT_YET_RECRUITING date: 2024-12-01 date: 2025-12-01 date: 2025-12-01 date: 2024-03-22 date: 2024-03-22 name: Lindsey Russell, MD class: OTHER name: Napo Pharmaceuticals, Inc. briefSummary: The objectives of this study are to evaluate the efficacy and safety of crofelemer treatment in adults affected by Short Bowel Syndrome (SBS) with an ileostomy on parenteral support (PS) in reducing output or PS needs. Crofelemer will be provided as a powder three times daily for 12 weeks and a 4 week follow up. . conditions: Short Bowel Syndrome studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Small exploratory study primaryPurpose: TREATMENT masking: NONE count: 6 type: ESTIMATED name: Crofelemer Oral Product measure: Ostomy output reduction measure: Change in average weekly Parenteral Support (PS) volume measure: Change in SBS-QoL (Short bowel syndrome quality of life) measure: Change in GSRS (Gastrointestinal Symptom Rating Scale) measure: Change in intestinal absorption of fluids and macronutrients with consequent reduction of macronutrient requirements in patients with SBS measure: Change in weekly need for parenteral electrolytes sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Cleveland Clinic Main Campus city: Cleveland state: Ohio zip: 44106 country: United States name: Lindsey A Russell, MD role: CONTACT lat: 41.4995 lon: -81.69541 hasResults: False
nctId: NCT06326632 id: RHPT/0022/023 briefTitle: Comparative Effectiveness Study of Constant-Load Versus Graded Aerobic Exercise in Obese Children With Bronchial Asthma overallStatus: COMPLETED date: 2022-10-30 date: 2023-12-07 date: 2023-12-07 date: 2024-03-22 date: 2024-03-22 name: Cairo University class: OTHER briefSummary: This study aimed to compare the effect of constant-load aerobic exercise (CL-AE) and graded aerobic exercise (G-AE) on cardiopulmonary fitness, and functional capacity in a cohort of obese children with bronchial asthma (BA).
A total of 78 children with BA were randomly assigned to the CL-AE group (n = 26, who underwent moderate-intensity aerobic training with the training load maintained at the same level throughout the entire program, besides the respiratory re-training program), the G-AE group (n = 26, received an intensity- and duration-graded aerobic training in addition to the respiratory re-training program), or the control group (n = 29, who only engaged in a respiratory re-training program). Interventions were administered three times/week for 12 successive weeks.
The cardiopulmonary fitness and functional capacity were evaluated in the three groups before and after the completion of the assigned interventions. conditions: Bronchial Asthma studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: A prospective, three-arm, randomized controlled trial primaryPurpose: TREATMENT masking: SINGLE maskingDescription: A single-blind protocol was adopted. The researcher who collected the data was blind to the allocation of treatment whoMasked: OUTCOMES_ASSESSOR count: 78 type: ACTUAL name: Constant-load Aerobic Exercise name: Graded Aerobic exercise name: Respiratory Re-training measure: Peak oxygen uptake measure: Six-minute walk test measure: Dyspnea measure: Fatigue sex: ALL minimumAge: 8 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Ragab K. Elnaggar city: Al Kharj state: Riyadh country: Saudi Arabia lat: 24.15541 lon: 47.33457 hasResults: False
nctId: NCT06326619 id: SurvSysT briefTitle: Survival Benefit of Primary Tumour Resection Compared to Systemic Therapy Alone in Stage IV Colorectal Cancer Patients acronym: SurvSysT overallStatus: COMPLETED date: 2012-01-01 date: 2020-12-31 date: 2020-12-31 date: 2024-03-22 date: 2024-03-22 name: Medizinische Hochschule Brandenburg Theodor Fontane class: OTHER name: Clinical-Epidemiological Cancer Registry Brandenburg-Berlin briefSummary: About 20-25 percent of all colorectal cancer patients are diagnosed with International Union Against Cancer (UICC) stage IV disease. The benefit of primary tumor resection in the palliative context is therefore of high concern. However, empirical evidence from randomized and observational studies is inconsistent.
The objective of the present study is to compare the survival of palliative stage IV colorectal cancer patients selected for primary tumor resection and systemic treatment (PTR+SYST) to patients with systemic treatment only (SYST). conditions: Colorectal Cancer conditions: Neoadjuvant Systemic Therapy studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 480 type: ACTUAL name: Primary tumor resection name: Systemic Therapy measure: Survival sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06326606 id: 23-MLS101-101 briefTitle: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 in Healthy Participants overallStatus: RECRUITING date: 2024-03 date: 2024-09 date: 2024-10 date: 2024-03-22 date: 2024-03-22 name: MycoMedica Life Sciences PBC class: INDUSTRY briefSummary: MLS101 is being developed as a low dose psilocybin, that can be administered to treat various neurological and psychiatric conditions.
The purpose of this clinical trial is to assess how safe and tolerated MLS101 is; to see how MLS101 is distributed and cleared by the body (pharmacokinetics); and to assess the psychedelic effects of MLS101 in healthy adult participants. conditions: Healthy Volunteers studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This is a randomized, double-blind, placebo-controlled, single ascending and multiple dose study to assess the safety, tolerability, and pharmacokinetics of MLS101 in healthy participants. The study consists of 2 parts:
Part 2: Multiple Dose study, doses and administration regimens are pending the results from Part 1 primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: Psilocybin name: Placebo measure: Incidence, severity, and seriousness of treatment-emergent adverse events (TEAEs) measure: Occurrence of clinically significant changes in physical examination, vital signs, ECGs, clinical laboratory tests, the Columbia-Suicide Severity Rating Scale (C-SSRS). measure: Pharmacokinetics of MLS101: maximum observed serum concentration (Cmax) measure: Pharmacokinetics of MLS10: area under the plasma concentration-time curve (AUC) measure: Pharmacokinetics of MLS101: time corresponding to the occurrence of Cmax (tmax) measure: Pharmacokinetics of MLS101: apparent terminal elimination half-life (t½) measure: Pharmacokinetics of MLS101: apparent total systemic clearance after oral administration (CL/F) measure: Pharmacokinetics of MLS101: apparent volume of distribution during the terminal phase (Vz/F) measure: Sensorial effects of MLS101 measure: Cognitive function sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: CMAX Clinical Research Pty Ltd status: RECRUITING city: Adelaide state: South Australia zip: 5000 country: Australia name: Eloise Spooner role: CONTACT phone: +61 8 7088 7900 email: eloise.spooner@cmax.com.au name: Sepehr Shakib role: PRINCIPAL_INVESTIGATOR lat: -34.92866 lon: 138.59863 hasResults: False
nctId: NCT06326593 id: P.T.REC/012/005049 briefTitle: Wii Aerobic Training in Inhalation-injury Children Post-thermal Burn overallStatus: RECRUITING date: 2024-02-22 date: 2024-05-25 date: 2024-06-01 date: 2024-03-22 date: 2024-03-22 name: MTI University class: OTHER briefSummary: Inhalation injury is a composite of multiple insults including: supra glottic thermal injury, subglottic airway and alveolar poisoning, and systemic poisoning from absorbed small molecule toxins. These contaminant insults independently affect each of the pulmonary functions as well as having a direct effect on systemic physiology. Further, anatomic characteristics can predispose patients to inhalation injury. For example, an infant will develop airway obstructions much faster than an adult due to reduced airway diameter. Understanding the contributions of each of these pathologies to the patient's disease is critical to managing inhalation injury.
Wii fit aerobic training gives similar results with traditional rehabilitation practices, it causes less energy costs. This suggests that it can be a suitable rehabilitation tool for adult and elderly people with low energy levels. A review showed that video games are safe and feasible in the children with lung complications. Children' balance, aerobic and cognitive functions, quality of life improved and depressive mood decreased. WII aerobic games also make children to communicate better with other family members. conditions: Inhalation Injury studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: Wii aerobic training name: conservative chest care measure: Forced vital capacity (FVC) measure: forced expiratory volume in 1 second (FEV1) measure: peak expiratory flow (PEF) measure: Upper and lower chest expansion (2nd intercostal space, xiphoid)]) measure: Functional capacity 6-Minute Walk Test (6-MWT) measure: Timed Up and Go test (TUG) sex: ALL minimumAge: 12 Years maximumAge: 17 Years stdAges: CHILD facility: Heba Elfeky status: RECRUITING city: Cairo zip: 6347113 country: Egypt name: ahmed m el fahl, phd role: CONTACT phone: 00201097782441 email: nn_ee_mm_oo@yahoo.com lat: 30.06263 lon: 31.24967 facility: Ahmed Mohamed Ahmed Abdelhady status: RECRUITING city: Cairo country: Egypt name: Ahmed El Fahl, ph.d role: CONTACT lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06326580 id: MS.22.09.2144 briefTitle: Clinical Prediction Model of Obstructive Sleep Apnea at Mansoura University Hospitals overallStatus: COMPLETED date: 2022-10-20 date: 2023-10-20 date: 2024-02-20 date: 2024-03-22 date: 2024-03-22 name: Mansoura University class: OTHER briefSummary: Obstructive sleep apnea syndrome (OSAS)is a sleep breathing disorder manifested by complete apnea or partial hypopnea obstruction of the upper airway, which often remains undiagnosed and untreated (Kuczynski, W., 2019). These episodes, which should be more than 5 per hour and last at least 10 s, can lead to a sleep fragmentation and hypoxia (Huon, L.-K.A., 2017). OSAS predominantly affects 26% of individuals between 30 and 70 years in the U.S (apnea hypopnea index ≥5 events per hour) (Schwartz, M., 2018).
The test of hypothesis is to design a clinical prediction model of obstructive sleep apnea from collected data of the patients having symptoms of obstructive sleep apnea and the results of their sleep study conditions: Osa Syndrome studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: OTHER count: 1129 type: ACTUAL measure: The recorded data of all patients which include all their symptoms and comorbidities as well as their use of any regular medications will be collected. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mansoura University city: Mansoura state: Dakhlia zip: 050 country: Egypt lat: 31.03637 lon: 31.38069 hasResults: False
nctId: NCT06326567 id: 84032 briefTitle: Comprehensive Connected Cancer Care (C4): Intervention Evaluation overallStatus: RECRUITING date: 2024-02-01 date: 2025-06 date: 2025-06 date: 2024-03-22 date: 2024-03-22 name: Timothy Mullett class: OTHER name: Merck Sharp & Dohme LLC briefSummary: The C4 program aims to provide a multi-level intervention program (Patient Level, Healthcare Team and Healthcare System Level) that improves the coordination of care with supportive/ancillary care providers and community services through the use of patient navigation and a digital needs assessment and a closed-loop referral system and improves patient-centered communication and engagement in care through skills training for the healthcare team and provision of culturally appropriate patient educational tools and resources. The program components incorporate three areas that are critical to improving patient-centered care: coordination of care, patient-centered communication and engagement, and psychosocial care and other supportive services. conditions: Cancer conditions: Health Care Utilization studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 300 type: ESTIMATED name: C4 Program measure: Change in Health Related Quality of Life (FACT-G7) measure: Overall Survival sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Kentucky status: RECRUITING city: Lexington state: Kentucky zip: 40506 country: United States name: Yvonne Taul, RN role: CONTACT phone: 859-323-2354 email: Yvonne.Taul@uky.edu lat: 37.98869 lon: -84.47772 hasResults: False
nctId: NCT06326554 id: 22-5933 briefTitle: Single Arm Pilot Trial of Virtual and In-person STEP2 acronym: STEP2 overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-01-01 date: 2025-01-01 date: 2024-03-22 date: 2024-03-22 name: University Health Network, Toronto class: OTHER briefSummary: The goal of this clinical trial is to assess the feasibility of offering oncology patients a referral to the outpatient palliative care clinic based on virtual symptom screening before oncology clinic appointments, and to qualitatively explore factors patients consider when deciding to accept or defer a visit to this clinic.
Participants will be asked to complete questionnaires assessing quality of life, symptom burden, depression, anxiety, and satisfaction with care at baseline, 2, 4, and 6 months. conditions: Oncology studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Single arm intervention primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 20 type: ESTIMATED name: Virtual and in-person Symptom screening with Targeted Early Palliative care (STEP2) measure: FACIT-PAL 14 measure: FACIT-PAL 14 measure: ESAS-r-CS measure: PHQ-9 measure: FAMCARE-P16 measure: Generalized Anxiety Disorder-7 measure: Patient Global Impression of Change sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06326541 id: okutan briefTitle: The Effect of Listening to the Holy Quran on Vital Signs in Coma Patients overallStatus: COMPLETED date: 2023-01-05 date: 2023-12-10 date: 2023-12-30 date: 2024-03-22 date: 2024-03-22 name: Bitlis Eren University class: OTHER briefSummary: The aim of this study is to examine the effect of the Holy Quran listened to to coma patients on their vital signs.
Does listening to the Holy Quran have a positive effect on the life values of coma patients? conditions: Sequelae of; Complications Surgical and Medical Care studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: single group pretest-posttest primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 72 type: ACTUAL name: music therapy measure: systolic blood pressure- (mmHg) measure: diastolic blood pressure- (mmHg) measure: pulse (number of beats/min) measure: body temperature (degrees Celsius) measure: saturation (%-oxygen saturation) sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Bitlis Eren University city: Bitlis zip: 13100 country: Turkey lat: 38.40115 lon: 42.10784 hasResults: False